ISi Arkansas • '9. BlueCross BlueShield Arkansas Blue Cross and Blue Shield Blue Choice Formulary Effective 10/01/2021 INTRODUCTION ........................................................................................................................................................................................................................ 4 PREFACE ................................................................................................................................................................................................................................... 4 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ........................................................................................................................................................ 4 DRUG LIST PRODUCT DESCRIPTIONS.................................................................................................................................................................................. 4 GENERIC SUBSTITUTION ........................................................................................................................................................................................................ 5 SPECIALTY MEDICATIONS ..................................................................................................................................................................................................... 5 PLAN DESIGN ........................................................................................................................................................................................................................... 6 PREVENTIVE SERVICES .......................................................................................................................................................................................................... 7 LEGEND ..................................................................................................................................................................................................................................... 7 ANALGESICS ............................................................................................................................................................................................................................ 8 NSAIDs ............................................................................................................................................................................................................................. 8 GOUT ............................................................................................................................................................................................................................... 8 OPIOID ANALGESICS ..................................................................................................................................................................................................... 8 VISCOSUPPLEMENTS ................................................................................................................................................................................................... 9 ANTI-INFECTIVES ..................................................................................................................................................................................................................... 9 ANTIBACTERIALS ......................................................................................................................................................................................................... 10 ANTIFUNGALS .............................................................................................................................................................................................................. 11 ANTIRETROVIRAL AGENTS ........................................................................................................................................................................................ 11 ANTITUBERCULAR AGENTS ....................................................................................................................................................................................... 12 ANTIVIRALS .................................................................................................................................................................................................................. 12 MISCELLANEOUS ......................................................................................................................................................................................................... 13 ANTINEOPLASTIC AGENTS .................................................................................................................................................................................................. 13 ALKYLATING AGENTS ................................................................................................................................................................................................. 13 ANTIMETABOLITES ...................................................................................................................................................................................................... 14 BIOSIMILARS ................................................................................................................................................................................................................ 14 HORMONAL ANTINEOPLASTIC AGENTS................................................................................................................................................................... 14 KINASE INHIBITORS .................................................................................................................................................................................................... 14 MULTIPLE MYELOMA ................................................................................................................................................................................................... 15 PROSTATE CANCER .................................................................................................................................................................................................... 15 MISCELLANEOUS ......................................................................................................................................................................................................... 15 CARDIOVASCULAR ................................................................................................................................................................................................................ 16 ACE INHIBITORS .......................................................................................................................................................................................................... 16 ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS .......................................................................................................................... 16 ACE INHIBITOR/DIURETIC COMBINATIONS .............................................................................................................................................................. 16 ADRENOLYTICS, CENTRAL ........................................................................................................................................................................................ 17 ALDOSTERONE RECEPTOR ANTAGONISTS ............................................................................................................................................................ 17 ANGIOTENSIN II RECEPTOR ANTAGONISTS/DIURETIC COMBINATIONS ............................................................................................................ 17 ANGIOTENSIN II RECEPTOR ANTAGONIST/CALCIUM CHANNEL BLOCKER COMBINATIONS ........................................................................... 17 ANTIARRHYTHMICS ..................................................................................................................................................................................................... 17 ANTILIPEMICS .............................................................................................................................................................................................................. 18 BETA-BLOCKERS ......................................................................................................................................................................................................... 18 BETA-BLOCKER/DIURETIC COMBINATIONS............................................................................................................................................................. 19 CALCIUM CHANNEL BLOCKERS ................................................................................................................................................................................ 19 DIGITALIS GLYCOSIDES ............................................................................................................................................................................................. 19 DIURETICS ...................................................................................................................................................................................................................